{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "RSC1",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "RSC1 A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper discusses how R-synuclein (RS) variants, including A30P, E46K, and A53T, are implicated in Parkinson’s disease (PD) through their role in forming fibrillar structures that accumulate as Lewy bodies. The study focuses on the binding properties of these variants to phospholipids, which is relevant to their pathogenicity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism by linking RS variant binding properties to PD pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Solution NMR spectroscopy was used to study the phospholipid binding properties of the variants. This technique is a standard method for studying protein-lipid interactions and is relevant to understanding RS variant pathogenicity.",
          "judgment": "Yes",
          "reasoning": "The general class of assay (NMR) effectively models the disease mechanism by providing residue-specific information about phospholipid binding modes, which are directly tied to the proposed pathogenicity of the variants."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper does not explicitly describe basic controls (e.g., wild-type protein) or replicates for the assay. However, it does compare the binding properties of the variants to those of wild-type RS.",
          "judgment": "Yes",
          "reasoning": "While basic controls are present in the form of comparisons to wild-type RS, there is no mention of known pathogenic or benign variant controls being used in the assay. Therefore, the functional evidence strength for this variant is considered supporting."
        }
      ],
      "evidence_strength": {
        "PS3": "supporting"
      }
    },
    {
      "variant_id": {
        "Gene": "RSC1",
        "Protein_Change": {
          "ref": "E",
          "alt": "K",
          "position": "46"
        },
        "variant_string_id": "RSC1 E46K"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper discusses how R-synuclein (RS) variants, including A30P, E46K, and A53T, are implicated in Parkinson’s disease (PD) through their role in forming fibrillar structures that accumulate as Lewy bodies. The study focuses on the binding properties of these variants to phospholipids, which is relevant to their pathogenicity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism by linking RS variant binding properties to PD pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Solution NMR spectroscopy was used to study the phospholipid binding properties of the variants. This technique is a standard method for studying protein-lipid interactions and is relevant to understanding RS variant pathogenicity.",
          "judgment": "Yes",
          "reasoning": "The general class of assay (NMR) effectively models the disease mechanism by providing residue-specific information about phospholipid binding modes, which are directly tied to the proposed pathogenicity of the variants."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper does not explicitly describe basic controls (e.g., wild-type protein) or replicates for the assay. However, it does compare the binding properties of the variants to those of wild-type RS.",
          "judgment": "Yes",
          "reasoning": "While basic controls are present in the form of comparisons to wild-type RS, there is no mention of known pathogenic or benign variant controls being used in the assay. Therefore, the functional evidence strength for this variant is considered supporting."
        }
      ],
      "evidence_strength": {
        "PS3": "supporting"
      }
    },
    {
      "variant_id": {
        "Gene": "RSC1",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "RSC1 A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper discusses how R-synuclein (RS) variants, including A30P, E46K, and A53T, are implicated in Parkinson’s disease (PD) through their role in forming fibrillar structures that accumulate as Lewy bodies. The study focuses on the binding properties of these variants to phospholipids, which is relevant to their pathogenicity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism by linking RS variant binding properties to PD pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Solution NMR spectroscopy was used to study the phospholipid binding properties of the variants. This technique is a standard method for studying protein-lipid interactions and is relevant to understanding RS variant pathogenicity.",
          "judgment": "Yes",
          "reasoning": "The general class of assay (NMR) effectively models the disease mechanism by providing residue-specific information about phospholipid binding modes, which are directly tied to the proposed pathogenicity of the variants."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper does not explicitly describe basic controls (e.g., wild-type protein) or replicates for the assay. However, it does compare the binding properties of the variants to those of wild-type RS.",
          "judgment": "Yes",
          "reasoning": "While basic controls are present in the form of comparisons to wild-type RS, there is no mention of known pathogenic or benign variant controls being used in the assay. Therefore, the functional evidence strength for this variant is considered supporting."
        }
      ],
      "evidence_strength": {
        "PS3": "supporting"
      }
    }
  ]
}